KRAS and lung adenocarcinoma: Most notably, lung adenocarcinoma (LUAD) harbors those driver mutations and rearrangements that can be therapeutically addressed, such as EGFR, BRAF, ALK, ROS1, RET, NTRK, and also KRAS (6, 7).